Targeting c-FLICE-like inhibitory protein (CFLAR) in cancer

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 2, 2013, Pages 195-201

  Fulda, Simone ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Autophagy; C FLIP; Cancer; Necroptosis

Indexed keywords

FLICE INHIBITORY PROTEIN; HISTONE DEACETYLASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEASOME INHIBITOR;

APOPTOSIS; DRUG TARGETING; GENETIC TRANSCRIPTION; HUMAN; MOLECULAR MECHANICS; NEOPLASM; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TURNOVER TIME;

CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL DEATH; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84872248771     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.736499     Document Type: Review

References (63)

1. Lockshin RA, Zakeri Z. Cell death in health and disease. J Cell Mol Med 2007;11:1214-24
2. Fulda S, Debatin KM. 5-Aza-2'-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene 2006;25:5125-33 (Pubitemid 44285981)
3. Taylor RC, Cullen SP, Martin SJ. Apoptosis: Controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008;9:231-41 (Pubitemid 351301823)
4. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 2008;19:325-31
5. Vandenabeele P, Galluzzi L Vanden Berghe T, et al. Molecular mechanisms of necroptosis: An ordered cellular explosion. Nat Rev Mol Cell Biol 2010;11:700-14
6. Fulda S. Autophagy and cell death. Autophagy 2012;8:1250-1
7. Eisenberg-Lerner A, Bialik S, Simon HU et al. Life and death partners: Apoptosis autophagy and the cross-talk between them. Cell Death Differ 2009;16:966-75
8. Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009;124:511-15
9. Shirley S, Micheau O. Targeting c-FLIP in cancer. Cancer Lett 2010; [Epub ahead of print]
10. Micheau O, Thome M, Schneider P et al. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 2002;277:45162-71 (Pubitemid 36159119)
11. Tenev T, Bianchi K, Darding M, et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 2011;43:432-48
12. Feoktistova M, Geserick P, Kellert B et al. cIAPs block ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell 2011;43:449-63
13. Galluzzi L, Vitale I, Abrams JM, et al. Molecular definitions of cell death subroutines: Recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012;19:107-20
14. Kaiser WJ, Upton JW, Long AB, et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 2011;471:368-72
15. Zhang H, Zhou X, McQuade T, et al. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature 2011;471:373-6
16. Oberst A, Dillon CP, Weinlich R, et al. Catalytic activity of the caspase-8-FLIP (L) complex inhibits RIPK3-dependent necrosis. Nature 2011;471:363-7
17. Lee JS, Li Q, Lee JY, et al. FLIP-mediated autophagy regulation in cell death control. Nat Cell Biol 2009;11:1355-62
18. Park D, Shim E, Kim Y, et al. C-FLIP promotes the motility of cancer cells by activating FAK and ERK, and increasing MMP-9 expression. Mol Cells 2008;25:184-95 (Pubitemid 351818994)
19. Stagni V, di Bari MG, Cursi S, et al. ATM kinase activity modulates Fas sensitivity through the regulation of FLIP in lymphoid cells. Blood 2008;111:829-37
20. Chaudhary PM, Eby MT, Jasmin A et al. Activation of the NF-kappaB pathway by caspase 8 and its homologs. Oncogene 2000;19:4451-60
21. Kataoka T, Tschopp J. N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-kappaB signaling pathway. Mol Cell Biol 2004;24:2627-36 (Pubitemid 38381257)
22. Kataoka T, Budd RC, Holler N, et al. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol 2000;10:640-8 (Pubitemid 30354699)
23. Golks A, Brenner D, Krammer PH et al. The c-FLIP-NH2 terminus (p22-FLIP) induces NF-kappaB activation. J Exp Med 2006;203:1295-305 (Pubitemid 43736598)
24. Skurk C, Maatz H, Kim HS, et al. The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J Biol Chem 2004;279:1513-25 (Pubitemid 38082681)
25. Salon C, Eymin B, Micheau O, et al. E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP(short). Cell Death Differ 2006;13:260-72 (Pubitemid 43102209)
26. Haga S, Terui K, Zhang HQ, et al. Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms. J Clin Invest 2003;112:989-98 (Pubitemid 38056314)
27. Ricci MS, Jin Z, Dews M, et al. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004;24:8541-55 (Pubitemid 39245075)
28. Micheau O, Lens S, Gaide O, et al. NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 2001;21:5299-305 (Pubitemid 32702435)
29. Bartke T, Siegmund D, Peters N, et al. p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 2001;20:571-80 (Pubitemid 32156181)
30. Ueffing N, Schuster M, Keil E, et al. Up-regulation of c-FLIP short by NFAT contributes to apoptosis resistance of short-term activated T cells. Blood 2008;112:690-8
31. Li W, Zhang X, Olumi AF. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP (L). Cancer Res 2007;67:2247-55 (Pubitemid 46424244)
32. Scuto A, Kirschbaum M, Kowolik C et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood 2008;111:5093-100
33. Martinez-Balbas MA, Bauer UM Nielsen SJ, et al. Regulation of E2F1 activity by acetylation. Embo J 2000;19:662-71 (Pubitemid 30093739)
34. Yuan ZL, Guan YJ, Chatterjee D, et al. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005;307:269-73 (Pubitemid 40116244)
35. Vervoorts J, Luscher-Firzlaff JM Rottmann S, et al. Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO Rep 2003;4:484-90 (Pubitemid 36789847)
36. Patel JH, Du Y, Ard PG, et al. The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol Cell Biol 2004;24:10826-34 (Pubitemid 39603138)
37. Pathil A, Armeanu S, Venturelli S, et al. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 2006;43:425-34
38. Chen F, Zhu HH, Zhou LF, et al. Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep 2010;23:1457-62
39. Chang L, Kamata H, Solinas G, et al. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 2006;124:601-13 (Pubitemid 43199444)
40. Kundu M, Pathak SK, Kumawat K et al. A TNF- and c-Cbl-dependent FLIP (S)-degradation pathway and its function in Mycobacterium tuberculosis-induced macrophage apoptosis. Nat Immunol 2009;10:918-26
41. Haag C, Stadel D, Zhou S, et al. Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells. Gut 2011;60:225-37
42. Fulda S, Meyer E, Debatin KM. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. Cancer Res 2000;60:3947-56 (Pubitemid 32204591)
43. Panner A, James CD, Berger MS, et al. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 2005;25:8809-23 (Pubitemid 41429073)
44. Guo F, Sigua C, Tao J, et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004;64:2580-9 (Pubitemid 38523916)
45. Aron JL, Parthun MR, Marcucci G et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 2003;102:652-8 (Pubitemid 36841988)
46. Watanabe K, Okamoto K, Yonehara S. Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ 2005;12:10-18 (Pubitemid 40090024)
47. Hernandez A, Thomas R, Smith F, et al. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery 2001;130:265-72 (Pubitemid 32721679)
48. Schuchmann M, Schulze-Bergkamen H Fleischer B, et al. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95-and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 2006;15:227-30
49. Frew AJ, Lindemann RK, Martin BP et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci USA 2008;105:11317-22
50. Bangert A, Cristofanon S, Eckhardt I et al. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene 2012; [Epub ahead of print]
51. Yerbes R, Lopez-Rivas A. Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL. Invest New Drugs 2012;30:541-7
52. Kerr E, Holohan C, McLaughlin KM et al. Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. Cell Death Differ 2012;19:1317-27
53. Liu X, Yue P, Chen S, et al. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 2007;67:4981-8 (Pubitemid 46910207)
54. Seki N, Toh U, Sayers TJ, et al. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways. Mol Cancer Ther 2010;9:1842-51
55. Zhao X, Qiu W, Kung J, et al. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: A gene expression profiling study with implications for potential combination therapies. Leuk Res 2008;32:275-85 (Pubitemid 351215533)
56. Conticello C, Adamo L, Giuffrida R et al. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J Clin Endocrinol Metab 2007;92:1938-42 (Pubitemid 46997213)
57. Koschny R, Holland H, Sykora J, et al. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res 2007;13:3403-12 (Pubitemid 46944929)
58. Sayers TJ, Brooks AD, Koh CY, et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003;102:303-10 (Pubitemid 36759669)
59. Unterkircher T, Cristofanon S Vellanki SH, et al. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res 2011;17:4019-30
60. Zou W, Liu X, Yue P, et al. PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Cancer Biol Ther 2007;6:99-106 (Pubitemid 46294186)
61. Kim YH, Jung EM, Lee TJ, et al. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic Biol Med 2008;44:1055-68
62. Kinoshita H, Yoshikawa H, Shiiki K et al. Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression. Int J Cancer 2000;88:986-91
63. Abedini MR, Muller EJ, Brun J, et al. Cisplatin induces p53-dependent FLICElike inhibitory protein ubiquitination in ovarian cancer cells. Cancer Res 2008;68:4511-17